Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 15/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27521299 | 0.91 | FLT1 (0.84) | FLT1EGFRKDR | |
| SCHEMBL7116606 | 0.90 | FLT1 (0.86) | FLT1EGFRKDR | |
| SCHEMBL7124447 | 0.90 | FLT1 (0.81) | FLT1EGFRKDR | |
| SCHEMBL7128083 | 0.90 | FLT1 (0.80) | FLT1EGFRKDR | |
| SCHEMBL7117773 | 0.89 | FLT1 (0.81) | FLT1EGFRKDR | |
| SCHEMBL7124175 | 0.89 | FLT1 (0.81) | FLT1EGFRKDR | |
| SCHEMBL7124970 | 0.89 | FLT1 (0.81) | FLT1EGFRKDR | |
| SCHEMBL7115461 | 0.89 | FLT1 (0.81) | FLT1EGFRKDR | |
| SCHEMBL7128224 | 0.89 | FLT1 (0.80) | FLT1EGFRKDR | |
| SCHEMBL7127576 | 0.88 | FLT1 (0.79) | FLT1EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101328186-A | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER PROD INC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | claimed |
| CN-1280580-A | Thienopyrimidine and thienopyridine derivatives as anticancer agents | PFIZER PROD INC (US) | 2001-01-17 | — | — | CN | claimed |
| EP-1028964-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | claimed |
| WO-1999024440-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-05-20 | — | — | WO | claimed |
| CN-101328186-A | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER PROD INC (US) | 2008-12-24 | — | — | CN | disclosed |
| US-20070213305-A1 | N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213305-A1 | N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007056215-A9 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA INC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007056214-A2 | N-ALKYL-N-ARYL-THIENOPYRIMIDIN-R-AMINES AND USES THEREOF | CYTOVIA, INC (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056215-A2 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056208-A2 | N-ARYLALKYL-THIENOPYRIMIDIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099941-A1 | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | disclosed |
| CN-1280580-A | Thienopyrimidine and thienopyridine derivatives as anticancer agents | PFIZER PROD INC (US) | 2001-01-17 | — | — | CN | disclosed |
| EP-1028964-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024440-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | FLT1 1043/4885EGFR 2961/4885KDR 2362/4885 |
| US-20070213305-A1 | N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP10, CASP4, CASP3 | FLT1 2574/4885EGFR 1334/4885KDR 2253/4885 |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, API5 | FLT1 1839/4885EGFR 1226/4885KDR 1574/4885 |
| US-20070099941-A1 | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP10, CASP3, CASP4 | FLT1 1253/4885EGFR 389/4885KDR 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.